This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
== Dynamical features == Alpha-helices in proteins may have low-frequency accordion-like motion as observed by the Raman spectroscopy and analyzed via the quasi-continuum model. Helices not stabilized by tertiary interactions show dynamic behavior, which can be mainly attributed to helix fraying from the ends.
Modern food and biological process engineering relies heavily on applications of genetic manipulation. By understanding plants and animals on the molecular level, scientists are able to engineer them with specific goals in mind. Among the most notable applications of such genetic engineering is the creation of disease or insect resistant plants, such as those modified to produce Bacillus thuringiensis, a bacterium that kills strain-specific varieties of insect upon consumption. However, insects are able to adapt to Bacillus thuringiensis strains, necessitating continued research to maintain disease-resistance.
This was confirmed to be as effective as the antibiotic vancomycin at inhibiting Clostridioides difficile infection without having a significant effect on the overall microbial composition of the gut. Glycerol solutions have been used for the preservation and storage of tissue grafts at ambient conditions as an alternative to frozen storage. Glycerol has also been incorporated as a component of bio-ink formulations in the field of bioprinting. The glycerol content acts to add viscosity to the bio-ink without adding large protein, saccharide, or glycoprotein molecules. It is on the World Health Organization's List of Essential Medicines for its use in treating atopic eczema.
Sources: en.wikipedia.org
The families of two missing people from Trinidad and Tobago identified them publicly and suspected they were killed in the 14 October strike; one family said their relative was a fisherman who traveled often to Venezuela and denied he was involved in trafficking drugs. MSNBC wrote that one had a drug-related charge from 2018, and the other had been released in 2021 after a prison sentence for a 2009 murder. In the Paria Peninsula of Sucre state in Venezuela, from which the first boat struck on 1 September allegedly originated, Venezuelan media reported the area was known for trafficking, although not necessarily by Tren de Aragua, and some family members stated that villagers had become involved in illicit activity out of economic necessity. Inhabitants describing a town in mourning published tributes containing photos of the deceased beginning early on 3 September. The deceased included eight persons from San Juan de Unare and three from a nearby town, Güiria. The New York Times reported that "Venezuelan security officials descended on San Juan de Unare, cut off the electricity and made clear that public pronouncements about the attacks were not welcome, according to four townspeople, including the niece of one of the victims." Associated Press journalist Regina Garcia Cano visited Sucre just after the first Venezuelan strike and interviewed dozens of people; she wrote of the "sources' very real fears of being punished—particularly by the Venezuelan government—for speaking to reporters".
The dalton's numerical value in terms of the fixed-h kilogram is an experimentally determined quantity that, along with its inherent uncertainty, is updated periodically. The 2022 CODATA recommended value of the atomic mass constant expressed in the SI base unit kilogram is:mu = 1.66053906892(52)×10−27 kg. The previous 2018 CODATA value was used in the traditional definition of the Avogadro number to obtain the value g/Da = 6.0221407620(18)×1023, which was then rounded to 9 significant figures (thus guaranteeing continuity, to the precision indicated) and used to define it at exactly that value for the 2019 redefinition of the mole. The mole is a unit of amount of substance used in chemistry and physics, such that the mass of one mole of a substance expressed in grams (i.e., the molar mass in g/mol or kg/kmol) is numerically equal to the average mass of an elementary entity of the substance (atom, molecule, or formula unit) expressed in daltons. For example, the average mass of one molecule of water is about 18.0153 Da, and the mass of one mole of water is about 18.0153 g. A protein whose molecule has an average mass of 64 kDa would have a molar mass of 64 kg/mol. However, while this equality can be assumed for practical purposes, it is only approximate, because of the 2019 redefinition of the mole.
=== HIV/AIDS === Ritonavir was initially approved in 1996 as a standalone antiretroviral protease inhibitor for the treatment of HIV-1 infection. Early pharmacokinetic and pharmacodynamic (PK-PD) observations revealed that while high-dose monotherapy (such as 600 mg twice daily) was effective at suppressing viral replication, it was associated with significant gastrointestinal toxicity and the rapid emergence of drug-resistant viral strains. However, researchers discovered that ritonavir is one of the most potent known inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme. Administering it at much lower doses (100–200 mg) significantly slows the metabolism of other co-administered drugs, boosting their plasma concentrations and extending their half-lives without causing severe side effects. Consequently, ritonavir's clinical application shifted; it is rarely used today for its independent antiviral activity. Instead, it is indicated almost exclusively as a pharmacokinetic enhancer (or "booster") in combination therapy alongside other, primary protease inhibitors (such as lopinavir, darunavir, or atazanavir) to improve their efficacy and reduce the pill burden for patients.
This can be achieved because dimethyl fumarate and monomethyl fumarate, as cell-permeable metabolites, can epigenetically regulate the expression of micro-RNA-21 via the metabolic-epigenetic interplay in developing immune cells. The main activity of dimethyl fumarate and monomethyl fumarate is considered to be immunomodulatory, resulting in a shift in T helper cells (Th) from the Th1 and Th17 profile to a Th2 phenotype. Inflammatory cytokine production is reduced by the induction of proapoptotic events, inhibition of keratinocyte proliferation, reduced expression of adhesion molecules and diminished inflammatory infiltrate within psoriatic plaques. The primary route of elimination is via exhalation of CO2, with small amounts excreted through urine or faeces. There is no evidence for dimethyl fumarate interaction with cytochrome P450 and the most common efflux and uptake transporters, and therefore no interactions are expected with medicinal products metabolised or transported by these systems.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.